DOPAR

LOE Approaching

levodopa

NDAORALTABLET
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease because it does not cross the blood-brain barrier. However, levodopa the metabolic precursor of dopamine, does cross the blood-brain…

Indications (1)

Clinical Trials (5)

NCT07227896N/ANot Yet Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Started Mar 2026
100 enrolled
Parkinson's Disease
NCT07382440N/ANot Yet Recruiting

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Started Jan 2026
120 enrolled
Parkinson's Disease
NCT07284342N/ARecruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

Started Nov 2025
103 enrolled
Advanced Parkinson's Disease
NCT06965374N/ARecruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

Started Jun 2025
270 enrolled
Parkinson Disease
NCT06916507N/ARecruiting

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Started May 2025
125 enrolled
Parkinson's Disease